AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06550999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laceration repair with adhesive strips
Description: Repair of the patient's facial laceration with adhesive strips
Study NCT06550999 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laceration repair with sutures
Description: Repair of the patient's facial laceration with sutures
Study NCT06284369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Developing, Evaluating and Testing Video Messages for a Smoking Cessation Campaign
Description: To explore how smokers reacted to the gain-framed and loss-framed video ad
Study NCT06284369 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Message Framing
Description: Gain- framed messages in health communication are constructed by framing a particular outcome as either a benefit or a cost, relative to a specific reference poin
Study NCT04898946 — intervention group
Intervention type: BIOLOGICAL
Intervention: CoronaVac Vaccine
Description: CoronaVac Vaccine
Study NCT04898946 — intervention group
Intervention type: BIOLOGICAL
Intervention: BNT162b2 Vaccine
Description: Covid-19 BNT162b2 Vaccine
Study NCT05021315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10% povidone iodine
Description: 50 women who received preoperative vaginal cleansing with 10% povidone iodine.
Study NCT06651671 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myofascial release
Description: THe treatment group was instructed to lay prone on the treatment table such that the skin on their upper back was visible. Participants then received direct and indirect myofascial release for 30 seconds each, performed by the same osteopathic physician.
Study NCT06651671 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham (No Treatment)
Description: The medical student gently placed their hands on the patients back for 60 seconds without manipulating the tissue in any way.
Study NCT06701123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: uMAT-R mobile app with coaching component
Description: uMAT-R recovery mobile app with coaching component
Study NCT05354167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: muscle energy technique
Description: the subject to sit comfortably and then stabilize the subject's distal humerus with one hand, then the forearm was supinated with the therapist another hand until resistance appeared. Holding the position the subject was asked to slowly pronate the forearm that is Isometric contraction against resistance for a period of 6-10 seconds with inhale and exhale, followed by slightly increasing supination until resistance was met once again. After 5 seconds of relaxation, the procedure was repeated 5 times during a single treatment session; this technique was applied in 2 sessions for a week for 4 weeks.
Study NCT05354167 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oscillating manual energy therapy
Description: It is also known as V-spread .The subject was asked to sit on a chair with the affected painful arm resting on the treatment table. Tender points were palpated. Then the therapist places the index and middle fingers of one hand in a V-shape around the tender point and placed the index finger of the other hand in the medial side of the elbow, diagonally across the located tender point. Gentle pressure was applied a few times using fingertips to the tissues alternatively from the medial and lateral sides to start the oscillations. On the initiation of oscillations, the application of pressure should be stopped and allow the oscillations to continue between the two points of contact on the subject's elbow.
Study NCT05540366 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy combined with aerobic exercise
Description: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions, combined with a 30 minutes aerobic exercise programme on a bike.
Study NCT05540366 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: 30 minutes of physical therapy with education, manual therapy and therapeutic exercise at both temporomandibular and cervical regions (same programme than the intervention group)
Study NCT06218043 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Restrict subjects' intake of iodine-containing foods
Description: Replace subjects' iodized salt with non-iodized salt.
Study NCT06026514 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B/HPIV3/S-6P
Description: Intranasal vaccine.
Study NCT04633434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Talk Parenting Skill for Alexa
Description: In a 4-week period, families use at home a prototype Bedtime Routine module of the Talk Parenting program, a smart speaker app designed to provide parents with in-situ experiential support for building positive family routines. The prototype Bedtime Routine module of Talk Parenting guides families in creating a healthy bedtime routine to foster healthy sleep habits, provide experiential practice in self-regulation skills, and promote a positive parent-child relationship.
Study NCT05647304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RGn550 5 Hz-PWM
Description: RGn550 with a 5 Hz-pulsed wave mode light emission
Study NCT05647304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: RGn550 10 Hz-PWM
Description: RGn550 with a 10 Hz-pulsed wave mode light emission
Study NCT05279807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zofenopril
Description: Film-Coated tablets administered orally once daily according instructions provided by Principal Investigator.
Study NCT05279807 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Tablets of 5mg and 10mg administered orally once daily according instructions provided by Principal Investigator.
Study NCT04695210 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual peer-to-peer support
Description: See arm description
Study NCT05053737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: One cycle of Atezolizumab will be administered by intravenous (IV) infusion at a fixed dose of 1200 mg. Atezolizumab should be administered within 7 days after initiation of of the first dose of SBRT.
Study NCT05053737 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: SBRT will be given 3 times on non-consecutive days over the course of 5 to 7 days. Radiation will target sites of gross disease only to minimized exposure to normal tissue.
Study NCT04534296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: early mobilization
Description: Early mobilization is a kind of rehabilitation strategy. When the safe standards are met, early mobilization will be performed on subjects randomized in EM group for 30 minutes each time, twice a day, from Monday to Friday. The detailed mobilization activities include bed repositioning，passive or active range of motion and stretching exercises, passive or active respiratory muscle strengthening, sitting in bed, transfer from lying to sitting at edge of bed. Progressive mobilization goals will be individualized for each subject daily, corresponding to their clinical conditions, developmental maturity, strength and endurance.
Study NCT04534296 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: routine care
Description: In this arm, no additional early rehabilitation interventions will be performed except for the routine clinical care, including the ventilation management, spontaneous breathing trials, choice of sedation and analgesia and routine nursing care including repositioning every 2 hours and bed head elevation.
Study NCT06422949 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hilotherm® Cooling treatment
Description: Patient will receive cooling treatment with Hilotherm® at hands and feet level from half an hour before taxol treatment start until half an hour after treatment end
Study NCT05797506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane (Avmacol Extra Strength)
Description: 4 Tablets of Sulforaphane (Avmacol Extra Strength) per day in patients with Chronic Kidney Disease, stages 3-4.
Study NCT05797506 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: These tablets will be matched placebos and will be provided by Avmacol.
Study NCT04845737 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sympathetic skin response measurement
Description: Sympathetic skin response(SSR) was studied with upper and lower extremity hand and foot recording of all participants, and amplitude and latency values will be recorded. SSR measurement will be made at room temperature of 25 ºC, while the patients are resting in the supine position. 6 mm silver disc electrodes will be used as the recording electrode.~The relationship between the patients' vitamin D levels and inflammatory response markers and their sympathetic skin responses will be investigated by statistical analysis.
Study NCT05813392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Digital Cognitive Behavioral Therapy for Insomnia
Description: a full self-help digital cognitive behavioral therapy for Insomnia (dCBT-I) through a smartphone APP
Study NCT04955210 — intervention group
Intervention type: OTHER
Intervention: Not applicable（Cohort study）
Description: This is a prospective observational study and does not include interventions.
Study NCT06636682 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FK-PC101
Description: Up to 7 doses of FK-PC101 will be administered intradermally between Day 1 and Day 180. The immune adjuvant Bacillus Calmette Guérin (BCG) will be given concurrently with Dose 1 (day 1) and Dose 2 (day 8).
Study NCT06636682 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care (SOC)
Description: Subject receives Investigator-defined standard of care, excluding adjuvant therapy. If prostate cancer recurs before 12 months after radical prostatectomy, subjects are eligible to receive up to 7 doses of intradermal FK-PC101 vaccine (first 2 given concurrently with BCG).
Study NCT00013117 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Telephone specialist consultation
Study NCT06195358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile Health (Smartphone) Application
Description: The intervention arm will receive the smartphone application, which has been designed to engage primary caregivers directly in the active monitoring of their infants' development, and to provide tailored feedback and support for the provision of nurturing care. Study staff will make an initial home visit (less than an hour) to install the application on the caregiver phone and demonstrate use and collect baseline data. Subsequently, in the intervention arm, staff will make monthly visits (approximately 15 minutes duration) to assess functionality of the smartphone and answer questions/reinforce use.
Study NCT06195358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Printed Caregiving Materials
Description: The control arm will receive printed caregiving materials. In the control arm, staff will make monthly visits (approximately 15 minutes duration) to ask if there are questions about the printed caregiving materials.
Study NCT04672369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBI939
Description: IBI939 injection
Study NCT04672369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab injection
Study NCT04672369 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sintilimab injection
Study NCT04764669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E2027
Description: Oral hypromellose capsules.
Study NCT05867030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: lenalidomide is administered orally
Study NCT05867030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: rituximab is administered intravenously
Study NCT05867030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib
Description: parsaclisib is administered orally
Study NCT05869591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban 5 MG [Eliquis]
Description: Pharmacokinetics and pharmacodynamics assessment of apixaban in patients with Child A or B liver cirrhosis
Study NCT05869591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban 60 MG [Lixiana]
Description: Pharmacokinetics and pharmacodynamics assessment of edoxaban in patients with Child A or B liver cirrhosis
Study NCT05652673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Early discontinuation of nivolumab maintenance therapy in patients with irresectable stage III or metastatic melanoma
Study NCT06414941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administration
Description: atients received dexmedetomidine (0.5 µg/kg over 10 min before the induction of anesthesia), and then dexmedetomidine was infused at a rate of 0.4 μg/kg/h until 20 min before the end of operation
Study NCT06414941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus low-dose esketamine administration
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 2 µg/kg/min until 20 min before the end of operation, respectively.
Study NCT06414941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine plus high-dose esketamine administration
Description: Patients received a bolus infusion of dexmedetomidine (0.5 µg/kg) and esketamine (0.5 mg/kg)over 10 min before the induction of anesthesia, and then dexmedetomidine were infused at a rate of 0.4 µg/kg/h and 4 µg/kg/min until 20 min before the end of operation, respectively.
Study NCT05699070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202211 100mg
Description: DWC202211 for 5 days~Aspirin 100mg
Study NCT05699070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202212 5mg
Description: DWC202212 for 3 days~Rabeprazole 5mg
Study NCT05699070 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWC202211 100mg + DWC202212 5mg
Description: DWC202211 + DWC202212 for 5 days~Aspirin 100mg, Rabeprazole 5mg
Study NCT03636958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perampanel
Description: Perampanel is an antiepileptic with a novel mechanism of action as it targets post-synaptic AMPA receptors. It has been shown to be effective as adjunctive therapy (dual therapy) for partial / focal epilepsy seizures and generalized in patients over 12 years of age.
Study NCT03636958 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional antiepileptic treatment
Description: choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
Study NCT03636958 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional antiepileptic treatment
Description: choice of the molecule is left to the discretion of the clinician excluding the following benzodiazepines: clobazam, clonazepam, diazepam. Antiepileptic drugs allowed are therefore: lamotrigine, levetiracetam, lacosamide, sodium valproate, carbamazepine, oxcarbabazepine, slicarbazepine, pregabalin, gabapentin, topiramate, phenytoin, phenobarbital, zonisamide, vigabatrin.
Study NCT06023784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left bundle branch area pacing
Description: Left bundle branch area pacing(LBBAP) is a novel physiological pacing form for ventricular pacing. In patients received LBBAP, the pacing lead will be placed at left bundle branch area to achieve narrow paced QRS duration.
Study NCT06023784 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: right ventricular pacing
Description: Right ventricular pacing is the traditional pacing modality for ventricular pacing. The pacing lead was placed in the apex or septum of right ventricle.
Study NCT05483244 — intervention group
Intervention type: OTHER
Intervention: discontinuous weaning
Description: Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. Patients of the discontinuous weaning group were disconnected from the respirator during the spontaneous breathing phases which could then take place via heat moist exchanger, high-flow therapy and/or speaking valve without pressure support by the respirator (spontaneous breathing trial with heat moist exchanger).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient.
Study NCT05483244 — intervention group
Intervention type: OTHER
Intervention: continuous weaning
Description: Each day, a respiratory therapist evaluated whether a spontaneous breathing trial could be performed. In the case of continuous weaning, spontaneous breathing trial was supported by the respirator, but the positive endexpiratory pressure was lowered to an individual level (between 5 and 10 mbar) resulting in very little pressure support (spontaneous breathing trial trial under continuous positive airway pressure condition).~Heart rate, respiratory rate, blood pressure and mental condition of the patient (i. e. stress, fear) were monitored carefully for five to ten minutes and the Rapid Shallow Breathing Index was calculated. If the patient could keep the Rapid Shallow Breathing Index stable under 105/min/l (without a significant increase) over five minutes, the spontaneous breathing trial was regarded as successful and the weaning could be started. The duration of spontaneous breathing trial was extended according to the individual situation of the patient.
Study NCT05498636 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Selinexor combined with Prednisone, Etoposide, and Lenalidomide
Description: Selinexor combined with Prednisone, Etoposide, and Lenalidomide
Study NCT06351605 — intervention group
Intervention type: DEVICE
Intervention: Valeda Light Delivery System
Description: The Valeda Light Delivery System will deliver two alternating and sequential treatments of 590 nm and 850 nm for 35 seconds, or a total of 70 seconds; and 660 nm for 90 seconds, or a total of 180 seconds.
Study NCT04707534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT04707534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone
Study NCT06572956 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T/CAR-NK cell injection
Description: One to two days after completion of eluvial chemotherapy, CAR-T/CAR-NK cells were transfused in subjects assessed by the investigators as eligible for infusion. The CAR-T/CAR-NK dose is calculated according to the patient's body weight, and the total number of cells transfused is about 1-2x106 /kg. Single intravenous infusion.
Study NCT06199986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ADT Order Check Attestation (Or)
Description: Clinical reminder order check in electronic health record
Study NCT06199986 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Script (Sc)
Description: Provider script added to progress note in electronic health record
Study NCT05660928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multidimensional intervention
Description: Multidimensional intervention, with mutidisciplinary approach.
Study NCT05052229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitric Oxide
Description: Nitric oxide gas for inhalation
Study NCT05052229 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Medical air
Description: Medical grade air for inhalation (placebo)
Study NCT05352022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monthly Unconditional Financial Incentive
Description: No requirements will be placed on how or where funds will be spent.
Study NCT05352022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weekly Food Purchasing Financial Incentive
Description: Incentive for healthy food purchases
Study NCT05352022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Glycemic Control Financial Incentive
Description: Incentive for absolute drop in HbA1c
Study NCT05352022 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Education
Description: mailed education information
Study NCT05493267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vγ2Vδ2 T lymphocyte-based immunotherapy
Description: Intravenous injection of zoledronic acid, followed by a subcutaneous injection recombinant human interleukin. Zoledronic acid was administered 3 times and recombinant human interleukin was administered 10 times for a total of 6 months.
Study NCT05493267 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treatment regimens for MDR-TB
Description: Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.
Study NCT05493267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment regimens for MDR-TB
Description: Treatment regimens was based on the principles of the WHO guidelines for the treatment of drug-resistant tuberculosis.